母代高脂饮食诱导子代在小鼠生命早期出现糖脂代谢紊乱且具有雄性易感性

目的：探讨孕期和哺乳期的高脂饮食能否导致子代在生命早期出现糖脂代谢紊乱。方法成年雌性C57BL/6J小鼠与正常饮食雄性小鼠进行交配,孕鼠随机分为高脂饮食组和正常饮食组,在孕期和哺乳期喂养高脂饲料或正常饲料,至交配后第一代鼠断乳时（3周龄）观察其糖脂代谢相关性指标以及肝脏病理表现。结果较正常饮食组子鼠相比,高脂饮食子鼠出生体重更低（ P＜0.05）。在断乳时,高脂饮食组雄性子鼠体重较重（ P ＝0.038）,腹腔糖耐量实验30 min和60 min血糖明显升高（P值分别为＜0.001和＜0.01）,糖耐量曲线下面积较大（P＝0.0016）,HOMA-IR值较大（P＜0.05）,雌性子鼠腹腔糖耐量实验在30 min血糖高于正常组（P＜0.01）,而糖耐量曲线下面积和HOMA-IR值在两组之间无明显统计学意义。雄性和雌性子代小鼠空腹胆固醇水平高脂饮食组均高于正常饮食组（ P值分别为＜0.0001和0.0004）,而两组雄性和雌性子代小鼠空腹胰岛素和甘油三酯水平差异均无显著性（ P均＞0.05）。另外,在断乳时高脂饮食子鼠出现肝脏脂肪变性,雌性和雄性子鼠无明显差异。结论母鼠孕期和哺乳期高脂饮食能够诱导子代在生命早期就能出现糖脂代谢紊乱并且雄性子鼠更易出现肥胖、糖耐量异常、胰岛素抵抗。     

高脂饮食诱导的C57BL/6J肥胖小鼠脂肪组织RIP140基因表达水平的研究(英文)

目的:探讨高脂饮食致肥胖小鼠脂肪组织RIP140mRNA表达水平的变化及其与胰岛素抵抗的关系。方法:将C57BL/6J雄性小鼠随机分为正常饮食(NFD)组、高脂饮食(HFD)组分别喂养14周后,测量两组小鼠体重,以NFD组小鼠体重作为对照,选取HFD组中体重大于对照组小鼠平均体重20%的小鼠作为肥胖组小鼠。对照组和肥胖组小鼠取血测甘油三酯(TG)、总胆固醇(TC)、空腹血糖(FBG)、空腹胰岛素水平(FIns),计算稳态模型胰岛素抵抗指数(HOMA-IR);采用RT-PCR技术检测两组小鼠附睾脂肪组织RIP140 mRNA的表达水平,并进行统计学分析。结果:HDF组小鼠中有12只符合标准计入肥胖组。肥胖组小鼠TG、TC、FBG、FIns(P0.05),HOMA-IR(P0.01)均明显高于对照组;肥胖组小鼠脂肪组织RIP140 mRNA的表达高于对照组,差异具有统计学意义(P0.05);相关分析显示小鼠脂肪组织RIP140 mRNA表达水平与TG水平呈正相关(r=0.536,P0.05),与胰岛素抵抗指数呈正相关(r=0.465,P0.05),而与TC、FBG、FIns水平相关分析无统计学意义(P0.05)。结论:高脂饮食诱导的肥胖小鼠脂肪组织RIP140 mRNA表达增加,并与胰岛素抵抗程度呈正相关。     

高脂饮食对西藏小型猪胰岛素抵抗及肝胰岛素受体底物1、2表达的影响

目的探讨高脂饮食对西藏小型猪胰岛素抵抗(IR)及肝胰岛素受体底物(IRS)1、2表达的影响。方法将10只西藏小型猪随机分为正常对照组(Ctr)5只饲喂普通饲料、IR模型(IR model)组5只饲喂高脂饲料,连续造模12周。造模12周后,称重并测量体长,计算体质量指数(BMI),空腹取前腔静脉血测定总胆固醇(TC)、低密度脂蛋白(LDL-C)、高密度脂蛋白(HDL-C)、甘油三酯(TG)、游离脂肪酸(FFA)、空腹血糖(FBG)和胰岛素(insulin),计算胰岛素抵抗指数(homeostasis model assessment-estimated insulin resistance,HOMA-IR);同时进行糖耐量试验,并计算糖耐量曲线下面积(AUC);取肝组织检测IRS-1和IRS-2基因和蛋白表达,并行油红O、PAS和HE染色,分别观察肝脂质沉积、糖原及组织病理变化。结果与正常对照组比,IR模型组体重、BMI指数、TC、LDL-C、HDL-C、FFA、FBG、insulin和HOMA-IR指数均显著升高(P0.05,P0.01);糖耐量试验显示血糖和胰岛素水平曲线下降延缓,而AUC_(血糖)和AUC_(胰岛素)均明显升高(P0.05,P0.01);肝组织中出现脂质沉积、糖原增加和局部肝细胞浊肿、部分胞核消失或被挤向一端,偶见淋巴细胞浸润;同时肝组织中IRS-1和IRS-2 mRNA和蛋白表达均显著降低(P0.05,P0.01)。结论高脂饮食可引起西藏小型猪胰岛素抵抗,肝组织IRS-1和IRS-2表达降低是高脂饮食影响西藏小型猪胰岛素敏感性的分子机制之一。     

甘草酸调控AMPK/ACC/SREBP信号通路改善胰岛素抵抗的机制

为了观察甘草酸对胰岛素抵抗的作用,探究其可能的机制,将50只C57BL/6J雄性小鼠随机分成正常组、模型组、甘草酸高剂量组、甘草酸低剂量组和二甲双胍组,每组10只。除正常组外,其余小鼠采用长期高脂饮食法,复制胰岛素抵抗模型,并给予相应药物进行干预。采用全自动生化仪测定小鼠血清中总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)和高密度脂蛋白胆固醇(HDL-C);检测小鼠血糖和胰岛素的水平,观察其糖耐量和胰岛素耐量变化;Western blotting法检测肝脏腺苷酸活化蛋白激酶(AMPK)、磷酸化乙酰辅酸A羟化酶(ACC)和固醇调节元件结合蛋白(SREBP)的表达。结果表明:长期高脂饮食的小鼠TC、TG和LDL-C明显升高,空腹血糖、血清胰岛素水平均明显升高,糖耐量和胰岛素耐量出现异常,肝脏AMPK和ACC的磷酸化水平和SREBP表达下降,与正常组小鼠相比,具有极显著性差异(P0.01)。经药物干预后,甘草酸高、低剂量组和二甲双胍组小鼠体质量下降,TC、TG和LDL-C明显降低,空腹血糖和血清胰岛素降低,糖耐量和胰岛素耐量异常得到改善,AMPK和ACC的磷酸化水平和SREBP表达升高,与模型组小鼠相比,具有显著性差异(P0.01,P0.05)。因此,本研究表明:甘草酸能够改善长期高脂饮食诱导的胰岛素抵抗,其机制可能与其调节肝脏AMPK/ACC/SREBP通路有关。     

木犀草素预防高脂膳食诱导的小鼠胰岛素抵抗的实验研究

目的:探讨黄酮类成分木犀草素对高脂饮食诱导的肥胖小鼠模型的胰岛素抵抗的影响。方法:30只C57BL/6J小鼠分正常饮食对照组(10只),高脂膳食组(对照组,10只)和高脂膳食加2%木犀草素组(木犀草素组,10只),干预16周,观察体重、血脂水平、血糖、胰岛素敏感性及胰岛素水平的变化。结果:小鼠在给予高脂膳食16周后,体重水平、血脂水平、血糖水平、胰岛素水平显著高于木犀草素组,胰岛素敏感性显著下降,与木犀草素组比较,P<0.05或P<0.01。而木犀草素组则可显著抑制体重、血脂、血糖及胰岛素水平的升高,与胰岛素敏感性未见明显下降,与正常对照组比较,P>0.05。结论:木犀草素可预防高脂膳食诱导的胰岛素抵抗。     

补硒对血糖受损大鼠胰岛素抵抗和胰岛素敏感性的影响

为了探讨补硒对空腹血糖受损大鼠血糖、胰岛素水平、胰岛素抵抗及胰岛素敏感性的影响,将40只大鼠随机分成4组,对照组、单纯高脂饲料组(HFD,饲料硒含量0.3 mg/kg),另外两组在HFD基础上添加富硒小麦(HFD+Se+,硒含量0.6 mg/kg;HFD+Se++,硒含量1.2 mg/kg)。实验前和实验第5周、10周、16周采血测定空腹血糖(FBG)和空腹胰岛素(FINS),计算胰岛素抵抗指数(HOMA-IR)和胰岛素敏感指数(ISI)。结果发现,无论补硒与否,高脂喂养大鼠体重明显高于对照组。从第10周开始3个高脂组FBG和FINS明显上升,提示空腹血糖受损。第16周时,HFD+Se+组和HFD+Se++组FINS显著低于HFD组,HFD+Se+和HFD+Se++组HOMA-IR显著低于HFD组,HFD+Se++组ISI显著高于HFD组。结果说明,补硒改善了空腹血糖受损大鼠的胰岛素抵抗,提高了胰岛素敏感性。     

玉竹多糖对流感病毒裂解疫苗的黏膜佐剂效应

探讨玉竹多糖(Polygonatum odoratun polysaccharides,POP)对流感病毒裂解疫苗黏膜免疫的佐剂效果。以BALB/c小鼠为模型,将H7N9流感病毒裂解疫苗单独或者添加不同剂量的POP(400、600、800、1 000和1200μg)做佐剂一次性滴鼻免疫小鼠,免疫三周后小鼠以致死剂量同源病毒攻击。实验结果表明,当在疫苗中加入1 000μg POP时,与疫苗单独免疫相比,单次滴鼻免疫就明显增强了小鼠抵抗致死量病毒感染的能力,体重丢失减少,肺部残余病毒滴度下降,存活率提高;血清中疫苗特异性IgG抗体和HI抗体以及鼻洗液中SIgA抗体都提高了;IgG亚类抗体检测显示,POP的加入显著增加了IgG1的抗体滴度,但抑制了IgG2a的产生,说明诱导的免疫应答偏向于Th2型。实验表明POP在一定剂量时能增强疫苗诱导的免疫应答,显示出黏膜佐剂效应。     

小鼠胰岛素抵抗哮喘模型的建立与评估

目的:探讨小鼠胰岛素抵抗哮喘模型的建立方法,并进行评估。方法:C57BL/6J小鼠随机分为4组:正常对照组(HC)、哮喘组(NIRA)均给予普通饲料喂养;胰岛素抵抗组IRNA)、胰岛素抵抗+哮喘组(IRA)均给予高脂饲料(D12492)喂养。每周称重,第6-14周,每周检测各组小鼠空腹血糖(FPG)、空腹血清胰岛素(FINS)水平,计算稳态模型胰岛素抵抗评价指数(HOMA-IR)评估胰岛素抵抗程度;小鼠胰岛素抵抗模型建立成功后在其基础上诱导哮喘模型,NIRA组和IRA组小鼠给予卵清蛋白(OVA)致敏、激发;HC组和IRNA组小鼠给予生理盐水作为对照,末次激发24后,制作肺病理切片,计数肺泡灌洗液(BALF)中白细胞总数及分类,检测血清和BALF中相关炎性因子的水平,比较各组小鼠胰岛素抵抗指数与哮喘评价指标,评估模型。结果:(1)第9周末,IRNA组、IRA组小鼠的HOMA-IR值均2.5,表明胰岛素抵抗小鼠模型建立成功;(2)肺组织病理切片中,HC组、IRNA组小鼠肺组织无炎症改变,NIRA组、IRA组炎细胞浸润明显,尤以IRA组更甚。(3)与HC组比较,NIRA组(P0.01)、IRA组(P0.01)BALF中白细胞总数、嗜酸性粒细胞比例明显增高;(4)血清中抗OVA特异性Ig E(P0.01)和Ig G1(P0.05)水平显著升高;(5)血清和BALF中IL-4(P0.01)、IL-17(P0.05)的水平明显升高,且IRA组(P0.05)明显高于NIRA组;IFN-γ(P0.05)的水平明显降低,且IRA组(P0.05)明显低于NIRA组。结论:用高脂饲料喂养C57BL/6J小鼠9周,可建立稳定的胰岛素抵抗模型,从第10周开始用OVA致敏、激发诱发哮喘,可成功建立稳定的胰岛素抵抗哮喘小鼠模型,为进一步研究胰岛素抵抗与哮喘相关机制奠定基础。     

不同佐剂肾综合征出血热纯化疫苗体液免疫效果的研究

在肾综合征出血热(HFRS)纯化疫苗原液中分别加入Al(OH)3、IL-2、GM-CSF、CFA等佐剂的一种或两种,以不加佐剂的纯化疫苗原液作为对照,分别免疫BALB/c小鼠,定期进行眼眶采血,用ELISA法检测血清中抗HFRS病毒的抗体水平。用不同佐剂的HFRS纯化疫苗免疫BALB/c小鼠后,其抗体产生的时间和滴度均不同。佐剂组与对照组相比抗体产生早且(或)滴度高,IL-2佐剂组在免后第3天就可以检测到抗体;联合使用两种佐剂组与单独使用一种佐剂组相比,抗体产生早、滴度高。结果表明,上述各种佐剂对HFRS纯化疫苗诱导BALB/c小鼠产生的免疫应答均有一定的增强作用;IL-2对早期免疫应答、早期抗体的产生有显著意义;联合应用两种佐剂疫苗的免疫效果优于只加其中一种佐剂的疫苗。     

阳离子脂质体DOTAP佐剂对H5N1流感病毒裂解疫苗免疫效果的影响

目的研究阳离子脂质体DOTAP佐剂对H5N1型流感病毒裂解疫苗免疫效果的影响。方法制备DOTAP阳离子脂质体流感病毒裂解疫苗(简称DOTAP流感裂解疫苗),检测其包封率。将BALB/c小鼠分为13组,分别用含0.1、1.0、10.0μg HA/只剂量以DOTAP、Al(OH)3、CPG-ODN为佐剂以及不含佐剂的流感裂解疫苗于0、21天皮下免疫,PBS作为对照组,用血凝抑制试验检测小鼠初次免疫后21、42天血清HI抗体滴度;用ELISA检测初次免疫后21、42天血清特异性IgG抗体、IgG1、IgG2a亚类抗体滴度,以及初次免疫后42天小鼠脾脏单个核细胞体外经抗原刺激后细胞因子IL-2、IL-4、IFN-γ的分泌水平。将BALB/c小鼠分为3组,分别用含不同DOTAP剂量(100、300、600μg/只)的DOTAP流感裂解疫苗于0、21天皮下免疫,检测初次免疫后21、42天小鼠血清HI抗体滴度和IgG抗体滴度。结果 DOTAP流感裂解疫苗粒径在300~400 nm,带正电荷,包封率在50%以上;DOTAP流感裂解疫苗诱导的HI抗体水平和特异性IgG抗体水平均高于流感裂解疫苗,而与铝佐剂和Cp G-ODN佐剂间差异无统计学意义;DOTAP流感裂解疫苗产生的抗体仍以IgG1亚类抗体为主,免疫后42天诱导的IgG2a亚类抗体水平高于流感裂解疫苗和铝佐剂,低于Cp G-ODN佐剂;DOTAP流感裂解疫苗免疫后既分泌高水平Th1型细胞因子IFN-γ,同时也分泌高水平Th2型细胞因子IL-4;不同DOTAP剂量的DOTAP流感裂解疫苗免疫后,其HI抗体滴度和IgG抗体滴度在低、中、高剂量组之间存在明显的量效关系。结论 DOTAP作为H5N1型流感病毒裂解疫苗的佐剂可显著提高流感裂解疫苗的免疫原性,其对体液免疫应答的增强作用不低于铝佐剂和Cp G-ODN佐剂,并具有诱导细胞免疫应答的能力。     

SGK1 抑制剂改善糖代谢紊乱的作用研究

目的:观察血清和糖皮质激素诱导的蛋白激酶1(serum and glucocorticoid-induced protein kinase1,SGK1)抑制剂对db/db小鼠糖代谢紊乱的改善作用,初步探讨该作用是否与改善脂肪组织功能紊乱有关。方法:将db/db小鼠随机分为db/db组、抑制剂组,同时设db/m组,db/db组、db/m组小鼠给予普通饲料喂养,抑制剂组小鼠给予含SGK1抑制剂的饲料喂养,干预8周。观察体重、摄食量、空腹血糖(fasting blood glucose,FBG)、糖化血红蛋白(glycosylated hemoglobin,Hb A1C),干预8周后行腹腔葡萄糖耐量试验(intraperitoneal glucose tolerance test,IPGTT)、腹腔胰岛素耐量试验(intraperitoneal insulin tolerance test,IPITT)。酶联免疫吸附测定(enzyme linked immunosorbent assay,ELISA)法检测血清空腹胰岛素(fasting insulin,FINS)水平,计算胰岛素抵抗指数(homeostasis model assessment of insulin resistance,HOMA-IR)及胰岛素敏感性指数(insulin sensitivity index,ISI)。实时定量荧光PCR(real-time PCR)法检测脂肪组织中SGK1、脂肪细胞因子m RNA表达水平。结果:干预8周后,抑制剂组体重、FBG、Hb A1C、IPGTT、IPITT均低于db/db组(P0.05),摄食量无明显差异。与db/db组相比,抑制剂组血清FINS有下降趋势,HOMA-IR明显降低,ISI明显升高(P0.05)。SGK1抑制剂干预治疗后,脂肪组织中SGK1、单核细胞趋化因子-1(monocyte chemotactic protein-1,MCP-1)、凝血酶元激活因子的抑制因子-1(plasminogen activator inhibitor 1,PAI-1)m RNA表达下降(P0.05),脂联素(adiponectin)m RNA表达无明显变化。结论:SGK1抑制剂干预治疗可一定程度改善db/db小鼠糖代谢紊乱,该作用可能部分与改善脂肪组织功能紊乱有关。     

下丘脑Orexin 对肥胖大鼠能量代谢的影响

目的:探讨下丘脑注射OXR-1选择性受体拮抗剂ACT-335827对肥胖大鼠代谢的效果。方法:通过高脂饮食建立肥胖大鼠模型,采用CODA 8通道高通量非侵入性血压系统(EMKA)测量血压;所有脂类都使用商品酶试剂盒和TOSHIBA-40FR全自动分析仪测量;空腹血糖采用葡萄糖氧化酶法;空腹胰岛素采用放射免疫法测定。肥胖大鼠出现代谢紊乱后,给予ACT-335827处理,检测大鼠体重、血压、脂肪、甘油三酯、总胆固醇、高密度脂蛋白、低密度脂蛋白、游离脂肪酸(NEFA)、瘦素、空腹血糖及空腹胰岛素等的变化。结果:与普通饮食组相比,经过10周高脂饮食,高脂饮食组大鼠体重显著升高(P0.05),给予ACT-335827处理后,普通大鼠的体重、血压、脂肪含量、脂代谢等均无明显变化;与高脂饮食和高脂饮食加生理盐水处理组大鼠比较,高脂饮食加ACT-335827处理组肥胖大鼠的体重显著下降(P0.05),腹部和附睾脂肪含量下降(P0.05),低密度脂蛋白、甘油三酯、总胆固醇、瘦素水平下降(P0.05),空腹血糖及空腹胰岛素也显著降低(P0.05),但血压、肠系膜脂肪和肩胛棕色脂肪、高密度脂蛋白和NEFA无明显变化(P0.05)。结论:ACT-335827对肥胖大鼠的代谢紊乱具有改善作用,对肥胖大鼠有一定的减肥作用。     

Gut microbiota-mediated xanthine metabolism is associated with resistance to high-fat diet-induced obesity

Resistance to high-fat diet-induced obesity (DIR) has been observed in mice fed a high-fat diet and may provide a potential approach for anti-obesity drug discovery. However, the metabolic status, gut microbiota composition, and its associations with DIR are still unclear. Here, ultraperformance liquid chromatography-tandem mass spectrometry-based urinary metabolomic and 16S rRNA gene sequencing-based fecal microbiome analyses were conducted to investigate the relationship between metabolic profile, gut microbiota composition, and body weight of C57BL/6J mice on chow or a high-fat diet for 8 weeks. PICRUSt analysis of 16S rRNA gene sequences predicted the functional metagenomes of gut bacteria. The results demonstrated that feeding a high-fat diet increased body weight and fasting blood glucose of high-fat diet-induced obesity (DIO) mice and altered the host-microbial co-metabolism and gut microbiota composition. In DIR mice, high-fat diet did not increase body weight while fasting blood glucose was increased significantly compared to chow fed mice. In DIR mice, the urinary metabolic pattern was shifted to a distinct direction compared to DIO mice, which was mainly contributed by xanthine. Moreover, high-fat diet caused gut microbiota dysbiosis in both DIO and DIR mice, but in DIR mice, the abundance of Bifidobacteriaceae, Roseburia, and Escherichia was not affected compared to mice fed a chow diet, which played an important role in the pathway coverage of FormylTHF biosynthesis I. Meanwhile, xanthine and pathway coverage of FormylTHF biosynthesis I showed significant positive correlations with mouse body weight. These findings suggest that gut microbiota-mediated xanthine metabolism correlates with resistance to high-fat DIO.     

EPO对高脂喂养小鼠棕色脂肪组织PRDM16、FGF21表达及STAT3磷酸化水平的影响

目的：探索促红细胞生成素（EPO）对高脂饲料（HFD）喂养小鼠血糖和血浆胰岛素水平、胰岛素抵抗指数（HOMA-IR）、糖耐量,以及棕色脂肪组织中含PR结构域蛋白16（PRDM16）、信号转导与转录激活因子3（STAT3）磷酸化水平（p-STAT3/STAT3）、成纤维细胞生长因子21（FGF21）mRNA以及蛋白质表达的影响,为肥胖及其并发症的发生机制提供线索。方法：20只高脂饲料喂养的C57BL/6J雄性小鼠随机分为对照组（HFD-Con）和EPO组（HFD-EPO）,两组分别腹腔注射生理盐水和EPO（200 IU/kg）,每周3次,连续4周。4周后检测两组动物的体重、血糖与血浆胰岛素水平、HOMA-IR及糖耐量的变化;分别使用实时定量PCR法和Western blot法检测棕色脂肪组织中PRDM16、STAT3、FGF21 mRNA和蛋白质水平。结果：腹腔注射EPO 4周后,HFD-EPO组小鼠体重为（26.65±0.85）g,HFD-Con组体重为（31.50±1.60）g,P<0.01。HFD-Con组血糖为（91.06±9.86）mg/dl,HFD-EPO组为（62.79±8.09）mg/dl,P<0.01;HFD-EPO组小鼠血浆胰岛素水平为（10.56±1.06）μU/ml,HFD-Con组为（13.2±1.1）μU/ml,P<0.01。与HFD-Con组比较,HFD-EPO组的糖耐量水平显著改善,胰岛素抵抗指数下降;HFD-EPO组动物棕色脂肪组织中PRDM16、FGF21mRNA以及蛋白质表达,p-STAT/STAT3水平均显著增加,两组小鼠肝脏中FGF21 mRNA含量、血浆中FGF21含量无明显差异。结论：EPO可能通过增加棕色脂肪组织中PRDM16表达促进棕色脂肪组织的分化,降低高脂喂养小鼠的血糖水平、改善高脂喂养小鼠的糖代谢状态。     

多囊卵巢综合征患者血清抗苗勒管激素与肥胖、胰岛素抵抗程度的相关性分析

目的:探讨多囊卵巢综合征(polycystic ovary syndrome,PCOS)患者血清抗苗勒管激素(anti-Müllerian hormone,AMH)水平与肥胖、胰岛素抵抗(insulin resistance,IR)程度的相关性。方法:选择在我院生殖中心就诊的139名PCOS患者为研究组,并以月经周期正常、因输卵管因素或男性因素导致不孕者48名作为对照组。检测和比较PCOS患者的血清AMH、性激素水平及代谢指标,分析血清AMH水平与PCOS患者肥胖、胰岛素抵抗程度的关系。结果:PCOS组患者体质量指数(body mass index,BMI)、黄体生成素(luteinizing hormone,LH)、睾酮(testosterone,T)、垂体泌乳素(pituitary prolactin PRL)、空腹血糖(fasting plasma glucose,FPG)、空腹胰岛素(fasting insulin,FINS)、稳态模型胰岛素抵抗指数(homenostasis models assessment-insulin resistance index,HOMA-IR)的水平均显著高于对照组(P0.05),PCOS组和对照组年龄、卵泡刺激素(follicle stimulating hormone,FSH)比较差异无统计学意义(P0.05)。PCOS各表型组的血清AMH浓度、LH/FSH比值均明显高于对照组(P0.05)。肥胖组患者的AMH浓度低于正常体重组,BMI、FPG、FINS、HOMA-IR、甘油三脂(triglycerides,TG)水平均高于正常体重组,LH、LH/FSH、高密度脂蛋白(high density lipoprotein,HDL-C)水平均低于正常体重组(P0.05)。高HOMA-IR组患者的血清AMH浓度、LH、LH/FSH水平均明显低于低HOMA-IR组,BMI、T、FPG、FINS、TG、低密度脂蛋白(low density lipoprotein,LDL-C)水平均高于低HOMA-IR组(P0.05)。PCOS患者血清AMH浓度和BMI及HOMA-IR均存在显著负相关。结论:PCOS患者血清的AMH水平较对照组明显升高,与其肥胖、胰岛素抵抗(IR)程度呈显著负相关。     

桂皮醛对高脂喂养小鼠糖脂代谢影响的实验研究

目的：探讨口服桂皮醛对高脂喂养小鼠（C57BL/6J 背景）糖脂代谢的影响。方法：采用雄性C57BL/6J小鼠作为研究对象,分 正常对照组（6 只）,高脂组（6 只）,高脂+ 桂皮醛（40 mg/kg,每天1 次）干预组（6 只）。桂皮醛以0.5 %羧甲基纤维素钠（CMC-Na） 溶解后口服灌胃,每天1 次;正常对照组和高脂组给予灌服等体积的CMC-Na,每天1 次,干预时间为3 月。每周观察体重、空腹血 糖,实验结束后观察胰岛素耐量（IPITT）、葡萄糖耐量（IPGTT）,观察各组小鼠的血脂水平（TC,TG,LDL-C,HDL-C）、胰岛素水 平、肠系膜脂肪重量及以HE 染色观察脂肪细胞形态。结果：在脂代谢方面,桂皮醛干预可显著防止高脂喂养小鼠的体重和血脂水 平的升高;高脂喂养小鼠肠系膜脂肪重量显著增加,HE 染色提示脂肪细胞显著增大;桂皮醛可显著防止肠系膜脂肪重量的增加 及脂肪细胞的变大。而在葡萄糖代谢方面,桂皮醛可显著降低高脂喂养小鼠血糖和胰岛素水平,改善小鼠的葡萄糖耐量和胰岛素 敏感性。结论：口服桂皮醛可显著改善高脂喂养小鼠的糖、脂代谢。     

Leptin responses to glucose infusions in obesity-prone rats

The secretion of leptin is dually regulated. In fasting animals, plasma leptin concentrations reflect body fat stores, whereas the incremental leptin response to fasting or refeeding most likely reflects insulin-mediated energy flux and metabolism within adipocytes. Impaired secretion of leptin in either pathway could result in obesity. We therefore measured plasma leptin concentrations in fasted animals and plasma leptin concentrations after an intravenous glucose infusion in a rat model of obesity. Young Sprague-Dawley (S-D) and Fischer 344 (F344) rats had similar percent body fat and fasting glucose and fasting leptin concentrations. However, F344 animals had higher insulin concentrations and leptin responses to intravenous glucose than did the S-D animals. The animals were then fed a control or high-fat diet for 6 wk. High-fat fed animals gained more weight and body fat than did the control fed animals. Control and high-fat fed F344 animals gained approximately 40% (P < 0.0001) more weight and >100% (P < 0.01) more body fat than did the S-D animals. Fasting leptin concentrations and leptin concentrations after intravenous glucose infusions and feeding were more than double (P < 0.05) in F344 animals compared with S-D animals. Whether an animal is fed a control or high-fat diet had little effect on the leptin response to intravenous glucose. In conclusion, young, lean F344 animals, before the onset of obesity, demonstrated a greater acute leptin response to intravenous glucose than similarly lean S-D animals. After a 6-wk diet, F344 animals had a greater percent increase in body weight and insulin resistance and exhibited higher fasting leptin concentrations and a greater absolute leptin response to intravenous glucose compared with the S-D animals. The chronic diet (control or high fat) had little impact on the acute leptin response to intravenous glucose. F344 animals exhibit leptin resistance in young, lean animals and after aging and fat accumulation.     

Role of PYK2 in the development of obesity and insulin resistance

Non-receptor proline-rich tyrosine kinase-2 (PYK2), which is activated by phosphorylation of one or more of its tyrosine residues, has been implicated in the regulation of GLUT4 glucose transporter translocation and glucose transport. Some data favor a positive role of PYK2 in stimulating glucose transport, whereas other studies suggest that PYK2 may participate in the induction of insulin resistance. To ascertain the importance of PYK2 in the setting of obesity and insulin resistance, we (1) evaluated the regulation of PYK2 in mice fed a high-fat diet and (2) characterized body and glucose homeostasis in wild type (WT) and PYK2(-/-) mice on different diets. We found that both PYK2 expression and phosphorylation were significantly increased in liver and adipose tissues harvested from high-fat diet fed mice. Wild type and PYK2(-/-) mice were fed a high-fat diet for 8 weeks to induce insulin resistance/obesity. Surprisingly, in response to this diet PYK2(-/-) mice gained significantly more weight than WT mice (18.7+/-1.2g vs. 9.5+/-0.6g). Fasting serum leptin and insulin and blood glucose levels were significantly increased in high-fat diet fed mice irrespective of the presence of PYK2 protein. There was a close correlation between serum leptin and body weight. Intraperitoneal glucose tolerance tests revealed that as expected, the high-fat diet resulted in increased blood glucose levels following glucose administration in wild type mice compared to those fed normal chow. An even greater increase in blood glucose levels was observed in PYK2(-/-) mice compared to wild type mice. These results demonstrate that a lack of PYK2 exacerbates weight gain and development of glucose intolerance/insulin resistance induced by a high-fat diet, suggesting that PYK2 may play a role in slowing the development of obesity, insulin resistance, and/or frank diabetes.     

Metabolic consequences of ENPP1 overexpression in adipose tissue

Ectonucleotide pyrophosphate phosphodiesterase (ENPP1) has been shown to negatively modulate insulin receptor and to induce cellular insulin resistance when overexpressed in various cell types. Systemic insulin resistance has also been observed when ENPP1 is overexpressed in multiple tissues of transgenic models and attributed largely to tissue insulin resistance induced in skeletal muscle and liver. Another key tissue in regulating glucose and lipid metabolism is adipose tissue (AT). Interestingly, obese patients with insulin resistance have been reported to have increased AT ENPP1 expression. However, the specific effects of ENPP1 in AT have not been studied. To better understand the specific role of AT ENPP1 on systemic metabolism, we have created a transgenic mouse model (C57/Bl6 background) with targeted overexpression of human ENPP1 in adipocytes, using aP2 promoter in the transgene construct (AdiposeENPP1-TG). Using either regular chow or pair-feeding protocol with 60% fat diet, we compared body fat content and distribution and insulin signaling in adipose, muscle, and liver tissues of AdiposeENPP1-TG and wild-type (WT) siblings. We also compared response to intraperitoneal glucose tolerance test (IPGTT) and insulin tolerance test (ITT). Our results show no changes in Adipose ENPP1-TG mice fed a regular chow diet. After high-fat diet with pair-feeding protocol, AdiposeENPP1-TG and WT mice had similar weights. However, AdiposeENPP1-TG mice developed fatty liver in association with changes in AT characterized by smaller adipocyte size and decreased phosphorylation of insulin receptor Tyr(1361) and Akt Ser(473). These changes in AT function and fat distribution were associated with systemic abnormalities of lipid and glucose metabolism, including increased plasma concentrations of fatty acid, triglyceride, plasma glucose, and insulin during IPGTT and decreased glucose suppression during ITT. Thus, our results show that, in the presence of a high-fat diet, ENPP1 overexpression in adipocytes induces fatty liver, hyperlipidemia, and dysglycemia, thus recapitulating key manifestations of the metabolic syndrome.